🇺🇸 FDA
Patent

US 9937156

Modulation of MRTF-A activity in pathologic fibrosis and wound healing

granted A61KA61K31/42A61K45/06

Quick answer

US patent 9937156 (Modulation of MRTF-A activity in pathologic fibrosis and wound healing) held by The Board of Regents of the University of Texas System expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/42, A61K45/06, A61K9/06, A61K9/08